|
A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study. |
|
|
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BluePrint Medicines; Bristol-Myers Squibb; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Synthon; Taiho Pharmaceutical |
Research Funding - ADC Therapeutics (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical |
|
|
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Research Funding - Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 |
Travel, Accommodations, Expenses - Lilly |
|
|
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst) |
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Exeter Pharmaceuticals; MediTech; Merck Sharp & Dohme; Novartis; Pfizer; Pfizer; Philips Healthcare; Philips Healthcare; Pierre Fabre; Puma Biotechnology; Roche; Roche; Sanofi/Aventis; Seagen; Zymeworks |
Research Funding - AstraZeneca (Inst); Genentech (Inst); Macrogenics (Inst); Novartis (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Roche (Inst); Synthon (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche |
|
|
Honoraria - AstraZeneca/MedImmune |
Consulting or Advisory Role - AstraZeneca/MedImmune |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Research Funding - AbbVie (Inst); Amgen (Inst); AstraZeneca (Inst); DSi (Inst); Genentech/Roche (Inst); Lilly (Inst); Nektar (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst) |
|
|
Stock and Other Ownership Interests - Amgen |
|
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Macrogenics; Merck; Pfizer; Polyphor; Roche/Genentech |
|
Research Funding - Eisai (Inst); Lilly (Inst); Macrogenics (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Lilly; Macrogenics; Polyphor |
|
|
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Novartis; Sermonix Pharmaceuticals |
Research Funding - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; Sermonix Pharmaceuticals |
|
|
Research Funding - Lilly (Inst) |
|
|
Research Funding - Loxo (Inst) |
|
|
Honoraria - AstraZeneca; Eisai; Novartis; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; Ono Pharmaceutical |
Research Funding - Ono Pharmaceutical |
|
|
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen |
|
|
Honoraria - DAEHWA Pharmaceutical; ISU ABXIS |
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; ISU Abxis; Lilly (Inst) |
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst) |
|
|
Research Funding - AstraZeneca (Inst); Bayer (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Other Relationship - Roche |
|
|
Consulting or Advisory Role - Agendia; AstraZeneca; Athenex; Bayer; Biovica; Eisai; Novartis; Olaris; Philips Electronics; Puma Biotechnology; Sanofi; Seagen |
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst) |
|
|
Honoraria - Gilead Sciences; Roche; Synthon |
Consulting or Advisory Role - Amcure; Amgen; Boehringer Ingelheim; G1 Therapeutics; Macrogenics; Novartis; Novartis; Radius Health; Roche; Servier |
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Pfizer; Roche Belgium |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
Honoraria - Genentech (Inst); Johnson & Johnson (Inst) |
Consulting or Advisory Role - Bayer (I); Merck (I); Novartis (I); Seagen (I) |
Speakers' Bureau - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst) |
Research Funding - Agios (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Phoenix Molecular Designs (Inst); Puma Biotechnology (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - Genentech; Merck |